Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
Requiring PA for novel topical treatments for psoriasis, such as the new two-compound product containing calcipotriene and betamethasone dipropionate (Taclonex((R)); Warner Chilcott (US), Inc.; marketed as Daivobet((R))/Dovobet((R)) outside US by LEO Pharma), is not likely to be cost-effective for a managed care organization.
In an elderly population with multiple comorbidities undergoing elective common major orthopedic procedures, approximately 2% of patients required readmission to the PACU. The most common problems requiring this step-up in care were cardiac and pulmonary, which resulted in an increased length of hospital stay. Patients with OSA and multiple comorbidities undergoing total knee arthroplasty carry an increased risk for postoperative complications.